Bronchoscopic intratumoral injection of tranexamic acid to prevent excessive bleeding during multiple forceps biopsies of lesions with a high risk of bleeding: a prospective case series

BMC Cancer

Adil Zamani¹ 

[1] Department of Pulmonary Medicine, Meram Medical Faculty, Necmettin Erbakan University, Akyokus Mevkii, Meram 42080, Konya, Turkey

关键词: Tranexamic acid;    Lung cancer;    Hemorrhage;    Bronchoscopy;    Biopsy;   

Others  :  859013
DOI  :  10.1186/1471-2407-14-143

 received in 2013-04-12, accepted in 2014-02-23,  发布年份 2014

【 摘 要 】

Background

Significant bleeding may occur following endobronchial forceps biopsy or brushing of necrotic or hypervascular tumors in the airways. In some cases, methods such as endobronchial instillation of iced saline lavage and epinephrine may fail to control bleeding. The present study evaluated the efficacy and safety of a new bronchoscopic technique using intratumoral injection of tranexamic acid (IIT) for control of bleeding during forceps biopsy in patients with endobronchial tumors with a high risk of bleeding.

Methods

The study was a prospective case series carried out in a single center. Bronchoscopic IIT was performed in those patients who had endoscopically visible tumoral lesions with persistent active bleeding following the first attempt at bronchoscopic sampling. Tranexamic acid (TEA) was injected through a 22-gauge Wang cytology needle into the lesion in nominal doses of 250–500 mg. After 2–3 minutes, multiple forceps biopsy specimens were obtained from the lesion.

Results

Of the 57 consecutive patients included in the study, 20 patients (35.1%) underwent bronchoscopic IIT. The first attempt in 18 patients was endobronchial forceps biopsy (EBB), and because of a high risk of bleeding, the first attempt for the remaining two patients, who were on continuous dual antiplatelet therapy (aspirin and clopidogrel), employed endobronchial needle aspiration (EBNA) as a precautionary measure. Following IIT, subsequent specimens were obtained using EBB in all patients. Multiple forceps biopsy specimens (3–10) were obtained from the lesions (8 necrotic and 12 hypervascular) without incurring active bleeding. The following histopathologic diagnoses were made: squamous cell carcinoma (n = 14), adenocarcinoma (n = 2), small-cell lung cancer (n = 3), and malignant mesenchymal tumor (n = 1). No side effects of TEA were observed.

Conclusions

Bronchoscopic IIT is a useful and safe technique for controlling significant bleeding from a forceps biopsy procedure and can be considered as a pre-biopsy injection for lesions with a high risk of bleeding.

Trial registration

ISRCTN23323895

【 授权许可】

   
2014 Zamani; licensee BioMed Central Ltd.

【 参考文献 】

• [1]British Thoracic Society Bronchoscopy Guidelines Committee, a Subcommittee of Standards of Care Committee of British Thoracic Society: British Thoracic Society guidelines on diagnostic flexible bronchoscopy. Thorax 2001, 56(Suppl 1):i1-i21.
• [2]Zamani A: Bronchoscopic intratumoral injection of tranexamic acid: a new technique for control of biopsy-induced bleeding. Blood Coagul Fibrinolysis 2011, 22:440-442.
• [3]Tüller C, Tüller D, Tamm M, Brutsche MH: Hemodynamic effects of endobronchial application of ornipressin versus terlipressin. Respiration 2004, 71:397-401.
• [4]Stubbs SE, Brutinel WM: Complications of bronchoscopy. In Bronchoscopy. Edited by Prakash UBS. Philadelphia: Lippincott-Raven; 1997:357-366.
• [5]Cordasco EM Jr, Mehta AC, Ahmad M: Bronchoscopically induced bleeding: a summary of nine years’ Cleveland clinic experience and review of the literature. Chest 1991, 100:1141-1147.
• [6]Prakash UBS, Freitag L: Hemoptysis and bronchoscopy-induced hemorrhage. In Bronchoscopy. Edited by Prakash UBS. Philadelphia: Lippincott-Raven; 1997:227-251.
• [7]Jin F, Mu D, Chu D, Fu E, Xie Y, Liu T: Severe complications of bronchoscopy. Respiration 2008, 76:429-433.
• [8]Steinfort DP, Herth FJ, Eberhardt R, Irving LB: Potentially fatal arrhythmia complicating endobronchial epinephrine for control of iatrogenic bleeding. Am J Respir Crit Care Med 2012, 185:1028-1030.
• [9]Solomonov A, Fruchter O, Zuckerman T, Brenner B, Yigla M: Pulmonary hemorrhage: a novel mode of therapy. Respir Med 2009, 103:1196-1200.
• [10]Márquez-Martín E, Vergara DG, Martín-Juan J, Flacón AR, Lopez-Campos JL, Rodríguez-Panadero F: Endobronchial administration of tranexamic acid for controlling pulmonary bleeding: a pilot study. J Bronchology Interv Pulmonol 2010, 17:122-125.
• [11]Ernst A, Eberhardt R, Wahidi M, Becker HD, Herth FJ: Effect of routine clopidogrel use on bleeding complications after transbronchial biopsy in humans. Chest 2006, 129:734-737.
• [12]Dasgupta A, Jain P, Minai OA, Sandur S, Meli Y, Arroliga AC, Mehta AC: Utility of transbronchial needle aspiration in the diagnosis of endobronchial lesions. Chest 1999, 115:1237-1241.
• [13]Mazzone P, Jain P, Arroliga AC, Matthay RA: Bronchoscopy and needle biopsy techniques for diagnosis and staging of lung cancer. Clin Chest Med 2002, 23:137-158. ix
• [14]McCormack PL: Tranexamic acid: a review of its use in the treatment of hyperfibrinolysis. Drugs 2012, 72:585-617.
• [15]Levi M: Should antifibrinolytics be given in all patients with trauma? Curr Opin Anaesthesiol 2012, 25:385-388.
• [16]Moen CA, Burrell A, Dunning J: Does tranexamic acid stop haemoptysis? Interact Cardiovasc Thorac Surg 2013, 17:991-994.
• [17]Cap AP, Baer DG, Orman JA, Aden J, Ryan K, Blackbourne LH: Tranexamic acid for trauma patients: a critical review of the literature. J Trauma 2011, 71:S9-S14.
• [18]Nilsson IM: Clinical pharmacology of aminocaproic and tranexamic acids. J Clin Pathol Suppl (R Coll Pathol) 1980, 14:41-47.
• [19]U.S. FDA: Cyklokapron (tranexamic acid injection) package insert. 2011. http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/019281s030lbl.pdf webcite
• [20]Dunn CJ, Goa KL: Tranexamic acid: a review of its use in surgery and other indications. Drugs 1999, 57:1005-1032.
• [21]Mahdy AM, Webster NR: Perioperative systemic haemostatic agents. Br J Anaesth 2004, 93:842-858.
• [22]Suojanen J, Sorsa T, Salo T: Tranexamic acid can inhibit tongue squamous cell carcinoma invasion in vitro. Oral Dis 2009, 15:170-175.
• [23]Weber CF, Görlinger K, Byhahn C, Moritz A, Hanke AA, Zacharowski K, Meininger D: Tranexamic acid partially improves platelet function in patients treated with dual antiplatelet therapy. Eur J Anaesthesiol 2011, 28:57-62.
• [24]British National Formulary: 61st ed. London: BMJ Group and Pharmaceutical Press; 2011.
• [25]Murgu S, Colt H: Role of the pulmonologist in ordering post-procedure molecular markers in non-small-cell lung cancer: implications for personalized medicine. Clin Lung Cancer 2013, 14:609-626.
• [26]Jett JR, Carr LL: Targeted therapy for non-small cell lung cancer. Am J Respir Crit Care Med 2013, 188:907-912.
• [27]Khoo KL, Lee P, Mehta AC: Endobronchial epinephrine: confusion is in the air. Am J Respir Crit Care Med 2013, 187:1137-1138.